KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Gains from Sales and Divestitures (2020 - 2022)

Historic Gains from Sales and Divestitures for GoodRx Holdings (GDRX) over the last 3 years, with Q4 2022 value amounting to $2.7 million.

  • GoodRx Holdings' Gains from Sales and Divestitures rose 2976.13% to $2.7 million in Q4 2022 from the same period last year, while for Dec 2022 it was $2.7 million, marking a year-over-year increase of 2976.13%. This contributed to the annual value of $2.7 million for FY2022, which is 2976.13% up from last year.
  • GoodRx Holdings' Gains from Sales and Divestitures amounted to $2.7 million in Q4 2022, which was up 2976.13% from $743000.0 recorded in Q3 2022.
  • GoodRx Holdings' 5-year Gains from Sales and Divestitures high stood at $2.7 million for Q4 2022, and its period low was $1000.0 during Q3 2020.
  • Its 3-year average for Gains from Sales and Divestitures is $895444.4, with a median of $513000.0 in 2021.
  • As far as peak fluctuations go, GoodRx Holdings' Gains from Sales and Divestitures surged by 5120000.0% in 2021, and later changed by 0.0% in 2022.
  • Quarter analysis of 3 years shows GoodRx Holdings' Gains from Sales and Divestitures stood at $1000.0 in 2020, then surged by 205200.0% to $2.1 million in 2021, then increased by 29.76% to $2.7 million in 2022.
  • Its Gains from Sales and Divestitures stands at $2.7 million for Q4 2022, versus $743000.0 for Q3 2022 and $546000.0 for Q2 2022.